Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Inherit Metab Dis ; 45(6): 1048-1058, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-35999711

RESUMO

Acetyl-CoA transporter 1 (AT-1) is a transmembrane protein which regulates influx of acetyl-CoA from the cytosol to the lumen of the endoplasmic reticulum and is therefore important for the posttranslational modification of numerous proteins. Pathological variants in the SLC33A1 gene coding for AT-1 have been linked to a disorder called Huppke-Brendel syndrome, which is characterized by congenital cataracts, hearing loss, severe developmental delay and early death. It has been described in eight patients so far, who all had the abovementioned symptoms together with low serum copper and ceruloplasmin concentrations. The link between AT-1 and low ceruloplasmin concentrations is not clear, nor is the complex pathogenesis of the disease. Here we describe a further case of Huppke-Brendel syndrome with a novel and truncating homozygous gene variant and provide novel biochemical data on N-acetylated amino acids in cerebrospinal fluid (CSF) and plasma. Our results indicate that decreased levels of many N-acetylated amino acids in CSF are a typical metabolic fingerprint for AT-1 deficiency and are potential biomarkers for the defect. As acetyl-CoA is an important substrate for protein acetylation, we performed N-terminal proteomics, but found only minor effects on this particular protein modification. The acetyl-CoA content in patient's fibroblasts was insignificantly decreased. Our data may help to better understand the mechanisms underlying the metabolic disturbances, the pathophysiology and the clinical phenotype of the disease.


Assuntos
Aminoácidos , Ceruloplasmina , Humanos , Acetilcoenzima A/metabolismo , Ceruloplasmina/metabolismo , Aminoácidos/metabolismo , Retículo Endoplasmático/metabolismo , Acetilação , Síndrome
2.
J Pediatr Endocrinol Metab ; 34(3): 389-393, 2021 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-33180048

RESUMO

OBJECTIVES: Hyperammonemia in a newborn is a serious condition, which requires prompt intervention as it can lead to severe neurological impairment and death if left untreated. The most common causes of hyperammonemia in a newborn are acute liver failure and inherited metabolic disorders. Several mitochondrial disorders have been described as a cause of severe neonatal hyperammonemia. CASE PRESENTATION: Here we describe a new case of adenosine-triphosphate (ATP) synthase deficiency due to m.8528T>C mutation as a novel cause of severe neonatal hyperammonemia. So far six patients with this mutation have been described but none of them was reported to need hemodialysis in the first days of life. CONCLUSION: This broadens the so far known differential diagnosis of severe neonatal hyperammonemia requiring hemodialysis.


Assuntos
Hiperamonemia/genética , Mutação , ATPases Translocadoras de Prótons/genética , Diálise Renal , Diagnóstico Diferencial , Feminino , Humanos , Hiperamonemia/diagnóstico , Hiperamonemia/terapia , Recém-Nascido , ATPases Translocadoras de Prótons/deficiência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA